Ignite Creation Date:
2024-05-06 @ 4:59 PM
Last Modification Date:
2024-10-26 @ 2:20 PM
Study NCT ID:
NCT05155592
Status:
UNKNOWN
Last Update Posted:
2021-12-13
First Post:
2021-12-09
Brief Title:
Reduction or Discontinuation of TNF-α Inhibitor in Non-infectious Uveitis Patients
Sponsor:
Dan Liang
Organization:
Sun Yat-sen University
Study Overview
Official Title:
Study of TNF-α Inhibitor Reduction or Discontinuation in Patients With Non-infectious Uveitis
Status:
UNKNOWN
Status Verified Date:
2021-12
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
TNF-α inhibitors like Adalimumab have good efficacy in non-infectious uveitis but long-term use can increase the risk of drugs and the patients financial burden is large The objective of this study was to explore the reduction or withdrawal of Adalimumab in uveitis patients with stable drug control and to evaluate the efficacy and safety of drug reduction in uveitis patients as well as the impact on their vision prognosis
Detailed Description:
TNF-α inhibitors like Adalimumab have good efficacy in non-infectious uveitis but long-term use will increase the risk of drugs and the patients financial burden is large Previous studies have reported that tapering or discontinuation of Adalimumab may be considered in patients with stable disease In clinical practice some important questions about the feasibility of dose reduction in individual patients and the withdrawal plan remain unanswered The objective of this study was to explore the reduction or withdrawal of Adalimumab in uveitis patients with stable drug control and to evaluate the efficacy and safety of drug reduction in uveitis patients as well as the impact on their vision prognosis
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None